Respimat Pharmaceuticals

The Respimat Pharmaceuticals Antitrust Litigation consolidates a small number of claims alleging anticompetitive conduct that delayed lower-cost generic competition for a Respimat-branded inhaler product, a fact pattern common to pharmaceutical antitrust cases involving device-dependent drug delivery. Centralized before Judge Denise J. Casper in the District of Massachusetts in August 2025, this is the smallest docket in the current antitrust group — only 2 actions are pending — reflecting either a narrow plaintiff population or a litigation still in its opening stage before additional related actions are identified and tagged in.

Funding availability in a docket this size is necessarily limited and highly fact-specific. With only two actions consolidated, there is not yet the volume needed to support a portfolio approach, and no certified class or damages framework exists to price individual claim value. Pharmaceutical antitrust claims of this type are typically brought by purchasers — direct purchasers, wholesalers, or payors — rather than injured patients, so this is a commercial overcharge claim rather than a personal-injury matter, and there is no medical-lien dimension to consider.

For a firm involved in one of the two pending actions, financing at this stage looks like firm-level litigation cost funding rather than claim-level advances, given the absence of a broader claimant pool to spread risk across. That calculus would change meaningfully if the MDL grows — pharmaceutical delayed-entry theories can attract additional purchaser plaintiffs once the initial pleadings clarify the alleged mechanism, and a larger, more mature docket would support the kind of portfolio underwriting available in bigger antitrust MDLs.

Criterica Capital's commercial litigation finance product remains the relevant path for counsel in this docket even at its current small scale. A structure and litigation brief on the case's procedural posture is also available for firms weighing capital against a docket that may still grow.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.